Australia's most trusted
source of pharma news
Monday, 04 May 2026
Posted 4 May 2026 AM
The TGA has approved Arrowhead Pharmaceuticals’ Redemplo for familial chylomicronemia syndrome (FCS), marking the siRNA specialist’s entry into the Australian market.
Self-administered via subcutaneous injection once every three months, the first-in-class siRNA therapeutic is designed to suppress the production of apoC-III, a protein produced in the liver that raises triglyceride levels by slowing their breakdown and clearance.

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.